Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jun;41(6):1301–1306. doi: 10.1128/aac.41.6.1301

Antimicrobial susceptibility of flavobacteria as determined by agar dilution and disk diffusion methods.

J C Chang 1, P R Hsueh 1, J J Wu 1, S W Ho 1, W C Hsieh 1, K T Luh 1
PMCID: PMC163904  PMID: 9174188

Abstract

A total of 106 clinical isolates of flavobacteria, including 41 isolates of Flavobacterium meningosepticum, 59 of Flavobacterium indologenes, and 6 of Flavobacterium odoratum were collected from January 1992 to December 1995 from patients in Taiwan. The in vitro activities of antimicrobial agents were determined concomitantly by the standard agar dilution and disk diffusion methods. More than 90% of the flavobacterial isolates were resistant to cephalothin, cefotaxime, ceftriaxone, moxalactam, aztreonam, imipenem, aminoglycosides, erythromycin, and glycopeptides. The majority of F. meningosepticum isolates were susceptible to piperacillin and to minocycline but resistant to ceftazidime, with MICs at which 90% of the isolates are inhibited being 8, 4, and > 128 microg/ml, respectively. Approximately half of the F. indologenes isolates were susceptible to piperacillin, cefoperazone, ceftazidime, and minocycline, with MICs at which 50% of the isolates are inhibited being 4, 16, 8, and 4 microg/ml, respectively. The majority of F. odoratum isolates were resistant to all the antimicrobial agents tested except minocycline, to which five of six isolates were susceptible. With least-squares regression analysis and error rate-bounded analysis methods, the following resistant and susceptible zone diameter breakpoints were established: < or = 12 and > or = 17 mm, respectively, for piperacillin against F. meningosepticum and F. indologenes; < or = 13 and > or = 18 mm, respectively, for ceftazidime against F. meningosepticum and F. indologenes, < or = 17 and > or = 21 mm, respectively, for ofloxacin against F. indologenes; < or = 16 and > or = 20 mm, respectively, for ciprofloxacin against F. meningosepticum. Valid breakpoints for the disk diffusion method could not be established for cefoperazone and ofloxacin against F. meningosepticum and for minocycline against F. meningosepticum and F. indologenes due to a poor correlation coefficient for the regression line or for cefoperazone and ciprofloxacin against F. indologenes due to the presence of remarkable error rates.

Full Text

The Full Text of this article is available as a PDF (182.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aber R. C., Wennersten C., Moellering R. C., Jr Antimicrobial susceptibility of flavobacteria. Antimicrob Agents Chemother. 1978 Sep;14(3):483–487. doi: 10.1128/aac.14.3.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Altmann G., Bogokovsky B. In-vitro sensitivity of Elavobacterium meningosepticum to antimicrobial agents. J Med Microbiol. 1971 May;4(2):296–299. doi: 10.1099/00222615-4-2-296. [DOI] [PubMed] [Google Scholar]
  3. Bradford P. A., Sanders C. C. Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam. Antimicrob Agents Chemother. 1992 Feb;36(2):394–400. doi: 10.1128/aac.36.2.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bruun B. Antimicrobial susceptibility of Flavobacterium meningosepticum strains identified by DNA-DNA hybridization. Acta Pathol Microbiol Immunol Scand B. 1987 Apr;95(2):95–101. doi: 10.1111/j.1699-0463.1987.tb03094.x. [DOI] [PubMed] [Google Scholar]
  5. Bucci F. A., Jr, Holland E. J. Flavobacterium meningosepticum keratitis successfully treated with topical trimethoprim-sulfamethoxazole. Am J Ophthalmol. 1991 Jan 15;111(1):116–118. doi: 10.1016/s0002-9394(14)76916-8. [DOI] [PubMed] [Google Scholar]
  6. Fass R. J., Barnishan J. In vitro susceptibilities of nonfermentative gram-negative bacilli other than Pseudomonas aeruginosa to 32 antimicrobial agents. Rev Infect Dis. 1980 Nov-Dec;2(6):841–853. doi: 10.1093/clinids/2.6.841. [DOI] [PubMed] [Google Scholar]
  7. GEORGE R. M., COCHRAN C. P., WHEELER W. E. Epidemic meningitis of the newborn caused by flavobacteria. II. Clinical manifestations and treatment. Am J Dis Child. 1961 Mar;101:296–304. doi: 10.1001/archpedi.1961.04020040024005. [DOI] [PubMed] [Google Scholar]
  8. Hawley H. B., Gump D. W. Vancomycin therapy of bacterial meningitis. Am J Dis Child. 1973 Aug;126(2):261–264. doi: 10.1001/archpedi.1973.02110190231025. [DOI] [PubMed] [Google Scholar]
  9. Hsueh P. R., Chen H. M., Huang A. H., Wu J. J. Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan. Antimicrob Agents Chemother. 1995 Oct;39(10):2239–2242. doi: 10.1128/aac.39.10.2239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hsueh P. R., Hsiue T. R., Hsieh W. C. Pyomyositis in intravenous drug abusers: report of a unique case and review of the literature. Clin Infect Dis. 1996 May;22(5):858–860. doi: 10.1093/clinids/22.5.858. [DOI] [PubMed] [Google Scholar]
  11. Hsueh P. R., Hsiue T. R., Wu J. J., Teng L. J., Ho S. W., Hsieh W. C., Luh K. T. Flavobacterium indologenes bacteremia: clinical and microbiological characteristics. Clin Infect Dis. 1996 Sep;23(3):550–555. doi: 10.1093/clinids/23.3.550. [DOI] [PubMed] [Google Scholar]
  12. Hsueh P. R., Teng L. J., Ho S. W., Hsieh W. C., Luh K. T. Clinical and microbiological characteristics of Flavobacterium indologenes infections associated with indwelling devices. J Clin Microbiol. 1996 Aug;34(8):1908–1913. doi: 10.1128/jcm.34.8.1908-1913.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hsueh P. R., Wu J. J., Hsiue T. R., Hsieh W. C. Bacteremic necrotizing fasciitis due to Flavobacterium odoratum. Clin Infect Dis. 1995 Nov;21(5):1337–1338. doi: 10.1093/clinids/21.5.1337. [DOI] [PubMed] [Google Scholar]
  14. Husson M. O., Izard D., Bouillet L., Leclerc H. Comparative in-vitro activity of ciprofloxacin against non-fermenters. J Antimicrob Chemother. 1985 Apr;15(4):457–462. doi: 10.1093/jac/15.4.457. [DOI] [PubMed] [Google Scholar]
  15. Jorgensen J. H., Maher L. A., Howell A. W. Activity of meropenem against antibiotic-resistant or infrequently encountered gram-negative bacilli. Antimicrob Agents Chemother. 1991 Nov;35(11):2410–2414. doi: 10.1128/aac.35.11.2410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lee E. L., Robinson M. J., Thong M. L., Puthucheary S. D. Rifamycin in neonatal flavobacteria meningitis. Arch Dis Child. 1976 Mar;51(3):209–213. doi: 10.1136/adc.51.3.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Maderazo E. G., Bassaris H. P., Quintiliani R. Flavobacterium meningosepticum meningitis in a newborn infant. Treatment with intraventricular erythromycin. J Pediatr. 1974 Nov;85(5):675–676. doi: 10.1016/s0022-3476(74)80515-9. [DOI] [PubMed] [Google Scholar]
  18. Metzler C. M., DeHaan R. M. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis. 1974 Dec;130(6):588–594. doi: 10.1093/infdis/130.6.588. [DOI] [PubMed] [Google Scholar]
  19. Ratner H. Flavobacterium meningosepticum. Infect Control. 1984 May;5(5):237–239. [PubMed] [Google Scholar]
  20. Scully B. E., Neu H. C. Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):179–185. doi: 10.1093/jac/18.supplement_d.179. [DOI] [PubMed] [Google Scholar]
  21. Sheridan R. L., Ryan C. M., Pasternack M. S., Weber J. M., Tompkins R. G. Flavobacterial sepsis in massively burned pediatric patients. Clin Infect Dis. 1993 Aug;17(2):185–187. [PubMed] [Google Scholar]
  22. Siegman-Igra Y., Schwartz D., Soferman G., Konforti N. Flavobacterium group IIb bacteremia: report of a case and review of Flavobacterium infections. Med Microbiol Immunol. 1987;176(2):103–111. doi: 10.1007/BF00200682. [DOI] [PubMed] [Google Scholar]
  23. Stamm W. E., Colella J. J., Anderson R. L., Dixon R. E. Indwelling arterial catheters as a source of nosocomial bacteremia. An outbreak caused by Flavobacterium Species. N Engl J Med. 1975 May 22;292(21):1099–1102. doi: 10.1056/NEJM197505222922105. [DOI] [PubMed] [Google Scholar]
  24. Strandberg D. A., Jorgensen J. H., Drutz D. J. Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli. Antimicrob Agents Chemother. 1983 Aug;24(2):282–286. doi: 10.1128/aac.24.2.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sundin D., Gold B. D., Berkowitz F. E., Schwartz D. A., Goo D. Community-acquired Flavobacterium meningosepticum meningitis, pneumonia and septicemia in a normal infant. Pediatr Infect Dis J. 1991 Jan;10(1):73–76. doi: 10.1097/00006454-199101000-00015. [DOI] [PubMed] [Google Scholar]
  26. Tam A. Y., Yung R. W., Fu K. H. Fatal pneumonia caused by Flavobacterium meningosepticum. Pediatr Infect Dis J. 1989 Apr;8(4):252–254. [PubMed] [Google Scholar]
  27. Thong M. L., Puthucheary S. D., Lee E. L. Flavobacterium meningosepticum infection: an epidemiological study in a newborn nursery. J Clin Pathol. 1981 Apr;34(4):429–433. doi: 10.1136/jcp.34.4.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Uchihara T., Yokota T., Watabiki S., Ueki M., Miyake S., Tsukagoshi H. Flavobacterium meningosepticum meningitis in an adult. Am J Med. 1988 Nov;85(5):738–739. doi: 10.1016/s0002-9343(88)80257-2. [DOI] [PubMed] [Google Scholar]
  29. Werthamer S., Weiner M. Subacute bacterial endocarditis due to Flavobacterium meningosepticum. Am J Clin Pathol. 1972 Mar;57(3):410–412. doi: 10.1093/ajcp/57.3.410. [DOI] [PubMed] [Google Scholar]
  30. Yabuuchi E., Ito T., Tanimura E., Yamamoto N., Ohyama A. In vitro antimicrobial activity of ceftizoxime against glucose-nonfermentative gram-negative rods. Antimicrob Agents Chemother. 1981 Jul;20(1):136–139. doi: 10.1128/aac.20.1.136. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES